Switzerland-based Octapharma to invest $1.5B on first US facility

to establish its first U.S. biopharmaceutical manufacturing facility in Rock Hill, South Carolina. to establish its first U.S. biopharmaceutical manufacturing facility in Rock Hill, South Carolina. to establish its first U.S. biopharmaceutical manufacturing facility in Rock Hill, South Carolina. Switzerland-based Octapharma said it willSwitzerland-based Octapharma said it willSwitzerland-based Octapharma said it willSwitzerland-based Octapharma said it willSwitzerland-based Octapharma said it willSwitzerland-based Octapharma said it willThe 50-acre campus will expand Octapharma’s capabilities to produce medicines derived from human plasma, according to a news release. Operations are scheduled to begin in the mid-2030s and include an administrative campus for Octapharma’s plasma donation operations.